Companies · Other Health Care

Venclose, Inc.

SAN JOSE · Other Health Care

Diligence memoA one-page analyst read on Venclose, Inc. — recommendation, valuation, rhythm, risks.
$27.1M
Total raised · real
1
Rounds
0.1×
Latest step-up
Top 14%
Sector rank · raised
Series B
Latest stage · inferred · Wed Jul 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Venclose, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.60× the median modeled value of Series B Other Health Care companies in 2019–2021 (78 peers) — value vs value, same stage and era.
Dormant
  • Last raise 7.0 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Venclose, Inc. is one of 5377 Other Health Care companies tracked from SAN JOSE. By capital raised it ranks in the upper tier (ahead of 87% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
41
Investors (latest)
2019-07-03
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries B · 2019-07-03 Raised $27M (real) Modeled valuation $600M (est)$27M$600MSeries B2019Seed · 2019-07-03 Raised $2.6M (real) Modeled valuation $65M (est)$2.6M$65MSeed2019+$2.6MCumulative $30M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$27.1M · 2019
Bridge · Series B-stage$2.6M · 2019smaller follow-on

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$600.3M
Base estimate est.
$63.7M
Conservative case
$2.3B
Upside case
$150.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series B · modeled $600.3M · 2019-07-032019Seed · modeled $64.7M · 2019-07-032019
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.36×/yr
Annual markup
1.64×/yr upside case
6.0 yr
Elapsed time used
7.0 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
7.0 yr
On record since
2019
First round
2
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 11× above median
This company$27.1M
Sector median$2.4M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.1× of median
This company$2.6M
Sector median$17.8M
Modeled value — vs sector median (estimate, all stages) 27× above median
This company$600.3M
Sector median$22.1M

Raised more than 87% of sector peers (real $). Modeled value above 94% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #13 of 78.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)KSMS Holdings, LLC · Series B Raised $40.0M · modeled $885.1M (est)Infab HoldCo, Inc. · Series B Raised $36.5M · modeled $807.5M (est)Aquity Holdings, Inc. · Series B Raised $36.0M · modeled $797.6M (est)MHH Management Holdco, LLC · Series B Raised $35.1M · modeled $777.6M (est)Earli Inc. · Series B Raised $40.0M · modeled $757.1M (est)Encore Dermatology, Inc. · Series B Raised $89.6M · modeled $729.9M (est)National Spine & Pain Centers Holdings, LLC · Series B Raised $32.0M · modeled $708.9M (est)In Vitro Sciences, LLC · Series B Raised $31.5M · modeled $697.9M (est)Lotus Parent, Inc. · Series B Raised $31.2M · modeled $690.4M (est)Iron Oak Holdings LLC · Series B Raised $30.0M · modeled $664.6M (est)Squid Ink, Inc. · Series B Raised $30.2M · modeled $621.4M (est)Predict Innovation Investors, Llc · Series B Raised $27.9M · modeled $617.4M (est)Venclose, Inc. (this company) Raised $27.1M · modeled $600.3M (est)Venclose, Inc.
CompanyStageRaised · realValue · estvs peer med.
KSMS Holdings, LLCSeries B$40.0M$885.1M2.36×
Infab HoldCo, Inc.Series B$36.5M$807.5M2.16×
Aquity Holdings, Inc.Series B$36.0M$797.6M2.13×
MHH Management Holdco, LLCSeries B$35.1M$777.6M2.08×
Earli Inc.Series B$40.0M$757.1M2.02×
Encore Dermatology, Inc.Series B$89.6M$729.9M1.95×
National Spine & Pain Centers Holdings, LLCSeries B$32.0M$708.9M1.89×
In Vitro Sciences, LLCSeries B$31.5M$697.9M1.86×
Lotus Parent, Inc.Series B$31.2M$690.4M1.84×
Iron Oak Holdings LLCSeries B$30.0M$664.6M1.78×
Squid Ink, Inc.Series B$30.2M$621.4M1.66×
Predict Innovation Investors, LlcSeries B$27.9M$617.4M1.65×
Venclose, Inc. this companySeries B$27.1M$600.3M1.60×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$27.1M2019-07-03$150.5M$600.3M90%
Seed$2.6M2019-07-03$13.1M$64.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$27.1M2019-07-03
    • First recorded raise — entered as Series B.
    • 67 investors on this round.
  2. Seed$2.6M2019-07-03
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 10.4× smaller than the prior — bridge or down round.
    • 41 investors on this round.
Intelligence
Modeled next raise
$2.6M
Modeled next size est.range $2.6M$4.2M
0.1×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
CHARLES CHON4 other2019-07
Jason Turner3 other2019-07
Jerry Gibson2 other2019-07
Peter Osborne1 other2019-07
Greg Vislocky2019-07
Registry & provenance

Venclose, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1782738
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
LoneStar Heart, Inc.Other Health CareSeries A$25.2M$84.4Mnetwork1 shared operator · same sector
Sesame, Inc.Other Health CareSeries B$27.0M$523.9Msame sector · same stage
VivoSense, Inc.Other Health CareSeries B$27.0M$332.6Msame sector · same stage
Aspire Bariatrics, LLCOther Health CareSeries B$27.0M$359.1Msame sector · same stage
GIO Blood LtdOther Health CareSeries B$27.3M$375.5Msame sector · same stage
Fresenius Medical Care Tulsa, LLCOther Health CareSeries B$26.8M$594.2Msame sector · same stage
DocAsap, Inc.Other Health CareSeries B$27.4M$398.8Msame sector · same stage
VoCare, Inc.Other Health CareSeries B$27.6M$443.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Velo-1, Inc.Other Health CareSeed$7.0M88%
Vertiflex, Inc.Other Health CareSeries C$1.0B88%
VeMiDoc, Inc.Other Health CarePre-Seed$8.9M87%
Verthermia Acquisition, Inc.Other Health CareSeries A$25.1M86%
Vesiflo, Inc.Other Health CareSeed$3.1M86%
Verdant Scientific, Inc.Other Health CarePre-Seed$562K86%
Verthermia, Inc.Other Health CarePre-Seed$7.7M86%
Vertera, Inc.Other Health CareSeed$75.9M86%
Frequently asked
How much funding has Venclose, Inc. raised?
Venclose, Inc. has raised approximately $27.1M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Venclose, Inc.'s estimated valuation?
Provath's modeled valuation for Venclose, Inc. is approximately $600.3M (modeled range $63.7M–$2.3B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Venclose, Inc. at?
Venclose, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Wed Jul 03.
What does Venclose, Inc. do and where is it based?
Venclose, Inc. operates in the Other Health Care sector, based in SAN JOSE.
Explore related

See where Venclose, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Venclose, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.